ArticleThe Journal of investigative dermatology2018
Topical Reformulation of Valsartan for Treatment of Chronic Diabetic Wounds.
Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- Clinical efficacy of chitosan-based hydrocolloid dressing in the treatment of chronic refractory wounds.International wound journal · 2022Trial
- GPCRs as key regulators in wound healing.Frontiers in cell and developmental biology · 2026Review
- Revisiting renin-angiotensin-aldosterone system in aging: translational insights from bench to bedside and back.The Journal of clinical investigation · 2025Review
- Evaluation of an Antioxidative Thermoresponsive Polydiolcitrate Hydrogel in a Novel Diabetic Pig Impaired Wound Healing Model.Regenerative engineering and translational medicine · 2025Article
- Angiogenesis during diabetic wound repair: from mechanism to therapy opportunity.Burns & trauma · 2025Review
- Co-Delivery of Valsartan and Metformin from a Thermosensitive Hydrogel-Nanoparticle System Promotes Collagen Production in Proliferating and Senescent Primary Human Dermal Fibroblasts.Biomacromolecules · 2024Article
- One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing.Molecules (Basel, Switzerland) · 2024Review
- Modeling diabetic endothelial dysfunction with patient-specific induced pluripotent stem cells.Bioengineering & translational medicine · 2023Article
- Potential use of angiotensin receptor blockers in skin pathologies.Iranian journal of basic medical sciences · 2023Review
- Adipose-derived mesenchymal stem cell-loaded β-chitin nanofiber hydrogel activates the AldoA/HIF-1α pathway to promote diabetic wound healing.American journal of stem cells · 2023Article
- Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells.Experimental gerontology · 2022Article
- Topical gel-based biomaterials for the treatment of diabetic foot ulcers.Acta biomaterialia · 2022Review
- Valsartan nano-filaments alter mitochondrial energetics and promote faster healing in diabetic rat wounds.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2021Article
- Wound Healing Driver Gene and Therapeutic Development: Political and Scientific Hurdles.Advances in wound care · 2021Review
- Emerging importance of ACE2 in external stratified epithelial tissues.Molecular and cellular endocrinology · 2021Review
- Development of Cephradine-Loaded Gelatin/Polyvinyl Alcohol Electrospun Nanofibers for Effective Diabetic Wound Healing: In-Vitro and In-Vivo Assessments.Pharmaceutics · 2021Article
- Electrospinning Proteins for Wound Healing Purposes: Opportunities and Challenges.Pharmaceutics · 2020Review
- Preparation andRSC advances · 2020Article
- Targeting the renin-angiotensin-aldosterone system in fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2020Review
- Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?Reviews in endocrine & metabolic disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 2 countries.
Funding
Abstract
Chronic wounds are among the most devastating and difficult to treat consequences of diabetes. Dysregulation of the skin renin-angiotensin system is implicated in abnormal wound healing in diabetic and older adults. Given this, we sought to determine the effects of topical reformulations of the angiotensin type 1 receptor blockers losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wound healing in diabetic and aged mice with further validation in older diabetic pigs. The application of 1% valsartan gel compared with other tested formulations and placebo facilitated and significantly accelerated closure time and increased tensile strength in mice, and was validated in the porcine model. One percent of valsartan gel-treated wounds also exhibited higher mitochondrial content, collagen deposition, phosphorylated mothers against decapentaplegic homologs 2 and 3 and common mothers against decapentaplegic homolog 4, alpha-smooth muscle actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/44 mitogen-activated protein kinase. Knockout of the angiotensin subtype 2 receptors abolished the beneficial effects of angiotensin type 1 receptor blockers, suggesting a role for angiotensin subtype 2 receptors in chronic wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.